TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27064
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with propranolol
Study: 30223023
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 single injection (6 mL)
Study: 28341759
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg daily) in Cohort R (R1)
Study: 28341759
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg every 12 hours) in Cohort NR (NR1)
Study: 28341759
Drug: Ritonavir (CYP3A4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (CYP3A4 inhibitor)
Study: 26667367
Drug: Eicosapentaenoic Acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic Acid (EPA) at 1,800 mg/day
Study: 19647862
Drug: 300-IR SLIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-IR SLIT tablets
Study: 14712427
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (menatetrenone, 45 mg/d)
Study: 7645443
Drug: Reactivating occupational
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactivating occupational therapy in addition to functional rehabilitation
Study: 29241395
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) administration
Study: 29090986
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure therapy (NPT) following cesarean section
Study: 27626390
Drug: The Incredible
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Incredible Years School Age Program (12 weekly 2-hour sessions)
Study: 19374795
Drug: Argatroban 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban 0.02 mg kg(‐1) h(‐1)
Study: 19374795
Drug: Argatroban 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban 0.04 mg kg(‐1) h(‐1)
Study: 19374795
Drug: Argatroban 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban 0.06 mg kg(‐1) h(‐1)
Study: 15136383
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 microg daily for 21 days)
Study: 11291825
Drug: Manual tracking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual tracking task using a hand-held stylus over a digitizing tablet
Study: 9108186
Drug: Pediatric formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric formulation of ciprofloxacin (125 mg per capsule)
Study: 9108186
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tablets of ciprofloxacin
Study: 8275921
Drug: Medifoxamine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medifoxamine (daily dose of 194 mg at day 28)
Study: 8275921
Drug: Imipramine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (daily dose of 161 mg at day 28)
Study: 2873890
Drug: ACVP (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACVP (doxorubicin, cyclophosphamide, and prednisolone in combination with vincristine)
Study: 2873890
Drug: ACTP (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTP (doxorubicin, cyclophosphamide, and prednisolone in combination with teniposide)
Study: 2873890
Drug: ACTVP (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTVP (doxorubicin, cyclophosphamide, and prednisolone in combination with both vincristine and teniposide)
Study: 29368152
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) followed by sentinel lymph node biopsy (SNB)
Study: 22377563
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg daily for 28 days followed by 14 days off (arm 1)
Study: 22377563
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg daily continuously (arm 2)
Study: 18714110
Drug: Enhanced intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced intervention (pharmacist case manager providing admission medication verification, medication teaching, discharge counseling, faxing discharge care plan, follow-up phone call)
Study: 16555577
Drug: Efonidipine (T‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efonidipine (T‐ and L‐type Ca2+ channel blocker)
Study: 16555577
Drug: Nifedipine (L‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (L‐type Ca2+ channel blocker)
Study: 12472980
Drug: Topical ibuprofen
Normalized name: ibuprofen Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ibuprofen gel (Ibugel) 5% applied for at least 7 days
Study: 12472980
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen 400 mg tablets (1200 mg daily) taken for at least 7 days
Study: 12472980
Drug: Topical ibuprofen
Normalized name: ibuprofen Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ibuprofen gel (Ibugel) 5%
Study: 12472980
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen 400 mg tablets (1200 mg daily)
Study: 1778334
Drug: Lederle-Takeda APDT
Normalized name: Pinus taeda pollen
DrugBank: Pinus taeda pollen (DB10744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle-Takeda APDT vaccine
Study: 1778334
Drug: Lederle DTP
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lederle DTP vaccine
Study: 1778334
Drug: Takeda APDT
Normalized name: Pinus taeda pollen
DrugBank: Pinus taeda pollen (DB10744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Takeda APDT vaccine
Study: 6168837
Drug: Perhexiline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline (100 mg twice daily)
Study: 31977740
Drug: Wireless oral
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless oral patient-controlled analgesia device for the delivery of oxycodone
Study: 31977740
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving PRN oxycodone from nursing staff
Study: 31088856
Drug: Genetic predisposition
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic predisposition to higher fasting insulin
Study: 19576082
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy scheme executed at day 1 and day 8 for 6 ‐ 8 cycles
Study: 19576082
Drug: ABVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD chemotherapy scheme executed at day 1 and day 15 for 6 ‐ 8 cycles
Study: 17381927
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin A supplementation
Study: 12540224
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg)
Study: 15041582
Drug: Control (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Vitamin C, 500 mg)
Study: 11697443
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (68 mg M-3-G)
Study: 11697443
Drug: Dealcoholized red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dealcoholized red wine (58 mg M-3-G)
Study: 11697443
Drug: Red grape
Normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red grape juice (117 mg M-3-G)
Study: 9129483
Drug: Regular milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular milk (240 mL)
Study: 9129483
Drug: Lactose-hydrolyzed milk
Normalized name: MILK PROTEIN,HYDROLYZED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-hydrolyzed milk (240 mL)
Study: 8199724
Drug: Felodipine (extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (extended release) 5-20 mg
Study: 8199724
Drug: Enalapril 5-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5-20 mg
Study: 8199724
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of felodipine and enalapril
Study: 31971474
Drug: Local heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local heat therapy (HT) applied to one thigh (garment perfused with water at 52°C) for 8 consecutive weeks (90 min, 5 days/wk)
Study: 31971474
Drug: Control thigh
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control thigh (no treatment)
Study: 31157554
Drug: Body lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body lipid (g/100g bodyweight)
Study: 25476120
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use assessments
Study: 24070632
Drug: 1% chlorhexidine-75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine-75% alcohol solution for cutaneous antisepsis
Study: 15522126
Drug: Toast with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toast with butter (17.5 g fat)
Study: 15522126
Drug: Cereal with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal with full-fat milk (17.5 g fat)
Study: 15522126
Drug: Cereal with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal with semi-skimmed milk (2.7 g fat)
Study: 15522126
Drug: Water (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (0 g fat)
Study: 2573768
Drug: Subcutaneous catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous catheter tunnelling (group B)
Study: 1102987
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride (50 mg twice daily) plus calcium carbonate (1 g four times daily)
Study: 19713092
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil (SO), 10mL x 3 daily for 10 days
Study: 19713092
Drug: Whale oil
Normalized name: castor oil fish whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whale oil (WO), 10mL x 3 daily for 10 days
Study: 9768370
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone once daily for 12 weeks
Study: 9768370
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily for 12 weeks
Study: 7849541
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake Group 1 (409 +/‐ 21 mg calcium/day)
Study: 7849541
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake Group 2 (663 +/‐ 16 mg calcium/day)
Study: 7849541
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake Group 3 (950 +/‐ 32 mg calcium/day)
Study: 7849541
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake Group 4 (1437 +/‐ 124 mg calcium/day)
Study: 2660862
Drug: Early consolidation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early consolidation with DATOP at lower dosage followed by maintenance chemotherapy
Study: 21884028
Drug: Erythropoietin stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin stimulating agents (ESA) - epoetin alfa
Study: 18264870
Drug: Recruitment strategies
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment strategies for RCTs in drug and alcohol treatment
Study: 17199193
Drug: Liposomal eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal eye spray (Tears Again)
Study: 17199193
Drug: Eye gel
Normalized name: EYE GEL
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eye gel containing triglycerides (Liposic)
Study: 15626589
Drug: Aspirin 50
Normalized name: aspirin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 50 mg daily for 5 consecutive days
Study: 15626589
Drug: Colorectal cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorectal cancer patients (without aspirin)
Study: 12663271
Drug: PEG-OB (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-OB (80 mg weekly for 46 days)
Study: 10052405
Drug: 8 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 microg/kg daily IL-10
Study: 10052405
Drug: IL-10 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 treatment
Study: 2150187
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg etodolac twice a day
Study: 2150187
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg piroxicam once a day
Study: 7191309
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 60 mg acemetacin
Study: 30593268
Drug: Delayed-start GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed-start GnRH antagonist protocol with estrogen priming followed by early follicular-phase GnRH antagonist treatment for 7 days before ovarian stimulation with gonadotropin
Study: 30593268
Drug: Standard GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GnRH antagonist protocol with estrogen priming
Study: 20571434
Drug: Aripiprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15 mg over a 14-day period)
Study: 18717374
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of MT(Implant) and MT(Tooth) values
Study: 16582545
Drug: Mg-rich mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-rich mineral water (281 mg/l)
Study: 16582545
Drug: Mg-rich mineral
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-rich mineral water (120 mg/l)
Study: 16582545
Drug: Low mineralized
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low mineralized water (8 mg/l)
Study: 16582545
Drug: Mg capsule
Normalized name: Tao 250mg Capsule
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg capsule (Magnesium‐Diasporal 150)
Study: 15006256
Drug: RLX +
Normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RLX + low‐dose transdermal estrogen (RLX + E)
Study: 8826517
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil 1 microgram/kg given 5 min before induction of anaesthesia (group A)
Study: 8826517
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil 1 microgram/kg given after ligation of the round ligaments of the uterus (group B)
Study: 1421710
Drug: Early high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high dose chemotherapy and autologous bone marrow transplantation (ABMT) rescue
Study: 6607596
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (24 hr of clear liquids plus two major laxatives plus tap-water enemas)
Study: 6607596
Drug: Colimmac lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colimmac lavage plus one major laxative
Study: 28862032
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin pre-treatment (Control)
Study: 29573941
Drug: Encorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib plus binimetinib (oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily)
Study: 29573941
Drug: Vemurafenib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (oral vemurafenib 960 mg twice daily)
Study: 29573941
Drug: Encorafenib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib (oral encorafenib 300 mg once daily)
Study: 26701234
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg I/mL iodine concentration
Study: 26701234
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg I/mL iodine concentration
Study: 24586292
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) administration
Study: 21038410
Drug: PEG IFN‐α2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 24 weeks
Study: 21038410
Drug: PEG IFN‐α2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG IFN‐α2a 180 μg subcutaneously weekly and weight‐based oral RBV 800 to 1,200 mg daily for 48 weeks
Study: 11563405
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) at maximally tolerated doses administered orally prior to and continuing for 48 hours following surgery
Study: 31400513
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention including behavior change goals, daily text messages with feedback, web-based weight gain graphs, health coaching, and a Facebook support group.
Study: 29160101
Drug: Peripheral nerve
Normalized name: Peripheral nerve antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral nerve block (7.5 mg/mL ropivacaine)
Study: 22728756
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg once daily for those ≥13 years or weight‐based dosing for children 1‐12 years)
Study: 19959338
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day plus mirtazapine 30 mg/day
Study: 17972359
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg/day plus placebo
Study: 18070637
Drug: Balanced injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced injection (steroid, lidocaine, bupivacaine, and bicarbonate, neutral pH)
Study: 18070637
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection (steroid, lidocaine, and bupivacaine alone, acidic pH)
Study: 6353278
Drug: Heparin (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (intravenous, given for 2 days)
Study: 25052972
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg submucosal dexamethasone injection
Study: 20222106
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneous 6 monthly)
Study: 20222106
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg oral weekly)
Study: 16959304
Drug: Nadroparine 2850
Normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparine 2850 units aXa/0.3 ml every 24 h during and 6 weeks after treatment
Study: 27067081
Drug: Desmopressin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin treatment
Study: 11472702
Drug: Heparin Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin Infusion Prior to Stenting
Study: 2494620
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (Control)
Study: 26748347
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acid (PUFA) treatment (docosahexaenoic acid (DHA) and eicosapentaenoic acid) (Omacor/Lovaza, 4 g/day)
Study: 17671229
Drug: Subtype B,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtype B, E, and D immunoglobulin G capture immunoassay
Study: 16223393
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg with fentanyl 15 microg
Study: 16223393
Drug: Bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 10 mg with fentanyl 15 microg
Study: 11962062
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antioxidants (vitamins E, C, beta-carotene) and minerals (zinc with copper)
Study: 7016567
Drug: Dipyridamole in
Normalized name: Dipyridamole Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole in combination with fenoterol
Study: 30461207
Drug: Amifostine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (200 mg/m2 IV)
Study: 19168537
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided corticosteroid and lidocaine injection in the subacromial bursa
Study: 19168537
Drug: Corticosteroid and
Normalized name: Corticosteroid and/or corticosteroid derivative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid and lidocaine injection in the gluteal region
Study: 21367933
Drug: rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (8 mg/d)
Study: 17148569
Drug: metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (2 g/d)
Study: 10191748
Drug: Vancomycin prophylaxis
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin prophylaxis in patients with large blood loss (greater than 2 L)
Study: 10191748
Drug: Vancomycin prophylaxis
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin prophylaxis in patients with small blood loss (less than 2 L)
Study: 10191748
Drug: Preoperative 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative 1.5 gram-dose of vancomycin for patients weighing more than 90 kg
Study: 2186854
Drug: Bestatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bestatin (30 mg daily after evacuation)
Study: 345342
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg glucagon
Study: 345342
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg glucagon
Study: 29788532
Drug: Epidural magnesium
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural magnesium sulphate (50 mg)